Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketofol
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Ketofol is a combination medication consisting of ketamine and propofol mixed together, typically in a 1:1 ratio. It is used for procedural sedation and analgesia, balancing the properties of both components. Ketofol functions through ketamine's NMDA receptor antagonism, providing analgesia, amnesia, and preserving respiratory drive, and propofol's GABA agonism, providing rapid sedation. The combination aims to counterbalance the adverse effects of each drug, such as propofol's hypotension and ketamine's psychomimetic effects.
- Brand names
- Ketofol
- Other names
- ketofol
02
Targets
GABRR (GABA-A receptor subunit rho)NMDAR (Glutamate receptor ionotropic, NMDA)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on ketofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketofol.